Ernst R. Berndt and Anjli C. Warner discuss their new book, U.S. Markets for Vaccines: Characteristics, Case Studies, and Controversies.

This volume offers a balanced and comprehensive snapshot of the changing landscape for vaccine markets.

Studies of vaccines have suffered from a focus on pricing and access, missing the crucial question of how they are developed and brought to market.

The only way to improve the availability of these products is to make it possible for firms to keep pace with rising production costs and earn enough returns to invest back in better manufacturing that enables stable, safe, and more scalable supply.

To sustain the fight against insect-borne diseases, we must improve research funding for public health insecticides.

We must begin to make our plans more broad-based to encompass the most threatening of pandemic scenarios.

A new proposal from the United Nations would alter the traditional role of drug companies and governments, leading to fewer drugs for developing world diseases.